✨ Free AI Report
CytoSorbents Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CytoSorbents Corporation
Company Research

CytoSorbents Corporation: Business Overview, Financials & Competitive Analysis

CytoSorbents Corporation scores 5/10 on the AskCyborg Cyborg Score (Mixed). Turnaround-stage blood purification company with demonstrated commercial traction but regulatory execution risk on key pipeline asset DrugSorb-ATR. Q3 2025 revenue of $9.5 million increased 10% year-over-year, showing organic growth momentum. However, the company faces near-term challenges with regulatory setbacks on DrugSorb-ATR and cash constraints requiring workforce reductions. A regulatory decision.

What is CytoSorbents Corporation's industry? CytoSorbents Corporation (cytosorbents.com) operates in Medical Devices - Critical Care Blood Purification. AskCyborg classifies CytoSorbents Corporation under Medical Devices - Critical Care Blood Purification in its company registry.

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification to treat life-threatening conditions in the intensive care unit & cardiac surgery. The company fo...

5/ 10Mixed

Cyborg Score thesis

Turnaround-stage blood purification company with demonstrated commercial traction but regulatory execution risk on key pipeline...

Read the full analyst-debate transcript →
Industry Medical Devices - Critical Care Blood Purification
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest CytoSorbents Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for CytoSorbents Corporation

AskCyborg analysts argue the bull and bear cases for CytoSorbents Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
CytoSorbents Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

CytoSorbents Corporation Overview

Pro stress-test →

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification to treat life-threatening conditions in the intensive care unit & cardiac surgery. The company focuses on a platform blood purification technology with two main products, CytoSorb and DrugSorb-ATR.

Strategic Profile

Pro stress-test →

CytoSorbents' adsorption technology broadens blood purification applications based on proprietary, biocompatible, and highly porous polymer bead technology designed to reduce elevated levels of harmful compounds from whole blood by hemoadsorption. As part of its strategic plan, CytoSorbents reduced its workforce by approximately 10% and now expects to reach operating cash flow break-even in the first quarter of 2026.

Competitive Landscape

Pro stress-test →

CytoSorbents competes in the extracorporeal blood purification market against other critical care and hemoadsorption device manufacturers. The company's competitive position is differentiated through its proprietary polymer bead technology and multi-indication pipeline across CytoSorb (inflammation/organ failure), DrugSorb-ATR (antithrombotic removal), and emerging products. Competition includes traditional dialysis providers and newer blood purification platforms, but CytoSorbents holds first-mover advantage in several therapeutic applications.

Industry Context

CytoSorbents Corporation operates in Medical Devices - Critical Care Blood Purification.

Key facts

Founded: 1997 · Headquarters: Princeton, New Jersey, US · Revenue: $37.0M

What the analysts stress-tested

The top findings that survived the multi-agent debate for CytoSorbents Corporation.

  • Q3 2025 revenue grew 10% YoY with record performance in distributor territories and near-record performance in direct sales outside core markets.
  • Company targets Q1 2026 operating cash flow breakeven through 10% workforce reduction and expense realignment.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Amended credit agreement with Avenue Capital providing $2.5M additional capital and extended interest-only period to December 31, 2026
  • November 2025Announced strategic workforce reduction of 10% targeting Q1 2026 cash flow breakeven
  • +2 moreTrack every material event for CytoSorbents Corporation as it happens. Explore monitoring →
Get alerted when CytoSorbents Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Extracorporeal membrane oxygenation (ECMO) systemsAdvanced cardiopulmonary support for critical care→Continuous renal replacement therapy (CRRT)Traditional dialysis and kidney support therapies→Hemoperfusion technologiesCompeting blood purification platforms→

Compare CytoSorbents Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CytoSorbents Corporation operates in Medical Devices - Critical Care Blood Purification. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Critical Care Blood Purification research →
NEW · MCP server

Ask your AI assistant about CytoSorbents Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CytoSorbents Corporation and its top competitor on Cyborg Score”
“What did CytoSorbents Corporation do this quarter?”
“Is CytoSorbents Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does CytoSorbents Corporation do?+
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification to treat life-threatening conditions in the intensive care unit & cardiac surgery. The company fo...
What is CytoSorbents Corporation's Cyborg Score?+
CytoSorbents Corporation has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CytoSorbents Corporation's main competitors?+
Named competitors include Extracorporeal membrane oxygenation (ECMO) systems, Continuous renal replacement therapy (CRRT), Hemoperfusion technologies. The full competitive landscape is in the AskCyborg report.
How can I get the full CytoSorbents Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CytoSorbents Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CytoSorbents Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.